StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
Shares of APVO stock opened at $0.41 on Thursday. The company has a 50 day moving average of $0.56 and a 200-day moving average of $3.08. Aptevo Therapeutics has a 12-month low of $0.28 and a 12-month high of $48.40.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share for the quarter, beating the consensus estimate of ($14.10) by $4.15. On average, sell-side analysts forecast that Aptevo Therapeutics will post -8.86 EPS for the current year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Using the MarketBeat Dividend Yield Calculator
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How to Invest in the Best Canadian Stocks
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
